Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Thierry Facon; Shaji K. Kumar; Torben Plesner; Robert Z. Orlowski; Philippe Moreau; Nizar Bahlis; Supratik Basu; Hareth Nahi; Cyrille Hulin; Hang Quach; Hartmut Goldschmidt; Michael O'Dwyer; Aurore Perrot; Christopher P. Venner; Katja Weisel; Joseph R. Mace; Tahamtan Ahmadi; Christopher Chiu; Jianping Wang; Rian Van Rampelbergh; Clarissa M. Uhlar; Rachel Kobos; Ming Qi; Saad Z. Usmani

doi:10.1182/blood-2018-120737

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Thierry Facon, Shaji K. Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Joseph R. Mace, Tahamtan Ahmadi, Christopher Chiu, Jianping Wang, Rian Van RampelberghClarissa M. Uhlar, Rachel Kobos, Ming Qi, Saad Z. Usmani

Research output: Contribution to journal › Journal article › Research

Original language	English
Journal	Blood
Volume	132
Issue number	Suppl. 1
ISSN	0006-4971
DOIs	https://doi.org/10.1182/blood-2018-120737
Publication status	Published - 29. Nov 2018
Event	60th ASH Annual Meeting - San Diego, United States Duration: 1. Dec 2018 → 4. Dec 2018

Conference

Conference	60th ASH Annual Meeting
Country/Territory	United States
City	San Diego
Period	01/12/2018 → 04/12/2018

Documents & Links

10.1182/blood-2018-120737

Cite this

Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Ahmadi, T., Chiu, C., Wang, J., ... Usmani, S. Z. (2018). Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). Blood, 132(Suppl. 1). https://doi.org/10.1182/blood-2018-120737

@article{c81506ea6e5943a3b14a8296b4ced9b7,

title = "Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)",

author = "Thierry Facon and Kumar, {Shaji K.} and Torben Plesner and Orlowski, {Robert Z.} and Philippe Moreau and Nizar Bahlis and Supratik Basu and Hareth Nahi and Cyrille Hulin and Hang Quach and Hartmut Goldschmidt and Michael O'Dwyer and Aurore Perrot and Venner, {Christopher P.} and Katja Weisel and Mace, {Joseph R.} and Tahamtan Ahmadi and Christopher Chiu and Jianping Wang and {Van Rampelbergh}, Rian and Uhlar, {Clarissa M.} and Rachel Kobos and Ming Qi and Usmani, {Saad Z.}",

year = "2018",

month = nov,

day = "29",

doi = "10.1182/blood-2018-120737",

language = "English",

volume = "132",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "Suppl. 1",

note = "60th ASH Annual Meeting ; Conference date: 01-12-2018 Through 04-12-2018",

}

Facon, T, Kumar, SK, Plesner, T, Orlowski, RZ, Moreau, P, Bahlis, N, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M, Perrot, A, Venner, CP, Weisel, K, Mace, JR, Ahmadi, T, Chiu, C, Wang, J, Van Rampelbergh, R, Uhlar, CM, Kobos, R, Qi, M & Usmani, SZ 2018, 'Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)', Blood, vol. 132, no. Suppl. 1. https://doi.org/10.1182/blood-2018-120737

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). / Facon, Thierry; Kumar, Shaji K.; Plesner, Torben et al.
In: Blood, Vol. 132, No. Suppl. 1, 29.11.2018.

Research output: Contribution to journal › Journal article › Research

TY - JOUR

T1 - Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

AU - Facon, Thierry

AU - Kumar, Shaji K.

AU - Plesner, Torben

AU - Orlowski, Robert Z.

AU - Moreau, Philippe

AU - Bahlis, Nizar

AU - Basu, Supratik

AU - Nahi, Hareth

AU - Hulin, Cyrille

AU - Quach, Hang

AU - Goldschmidt, Hartmut

AU - O'Dwyer, Michael

AU - Perrot, Aurore

AU - Venner, Christopher P.

AU - Weisel, Katja

AU - Mace, Joseph R.

AU - Ahmadi, Tahamtan

AU - Chiu, Christopher

AU - Wang, Jianping

AU - Van Rampelbergh, Rian

AU - Uhlar, Clarissa M.

AU - Kobos, Rachel

AU - Qi, Ming

AU - Usmani, Saad Z.

PY - 2018/11/29

Y1 - 2018/11/29

U2 - 10.1182/blood-2018-120737

DO - 10.1182/blood-2018-120737

M3 - Journal article

SN - 0006-4971

VL - 132

JO - Blood

JF - Blood

IS - Suppl. 1

T2 - 60th ASH Annual Meeting

Y2 - 1 December 2018 through 4 December 2018

ER -